By Denny Jacob

 

Abbott Laboratories disclosed that the first global procedures have been conducted using its new Volt Pulsed Field Ablation system to treat patients battling common abnormal heart rhythms such as atrial fibrillation.

The healthcare-products manufacturer said over 30 patients were treated in Australia as part of its clinical study evaluating the safety and effectiveness of its Volt PFA system. The company expects approval for its U.S. clinical trial for the system in the first half of this year.

Abbott said patients requiring a cardiac ablation procedure to treat conditions like atrial fibrillation received radiofrequency ablation, which uses heat to destroy tissue responsible for erratic heart signals, or cryogenic ablation, which freezes tissue. The company's system uses high-energy electrical impulses to destroy the cells causing abnormal heart rhythms, rather than heat or extreme cold, which it said can reduce the risk of damaging adjacent tissue in patients with complex disease or anatomy.

 

Write to Denny Jacob at denny.jacob@wsj.com

 

(END) Dow Jones Newswires

January 18, 2024 09:33 ET (14:33 GMT)

Copyright (c) 2024 Dow Jones & Company, Inc.
Abbott Laboratories (NYSE:ABT)
Gráfico Histórico do Ativo
De Mar 2024 até Abr 2024 Click aqui para mais gráficos Abbott Laboratories.
Abbott Laboratories (NYSE:ABT)
Gráfico Histórico do Ativo
De Abr 2023 até Abr 2024 Click aqui para mais gráficos Abbott Laboratories.